ReviewCancers2022
Immune Reconstitution Inflammatory Syndrome Associated Kaposi Sarcoma.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 23 citations in OpenAlex.
- Oral Kaposi Sarcoma With Clinical Features Suggestive of Concurrent Multicentric Castleman Disease in Advanced AIDS.Cureus · 2026Article
- Kaposi sarcoma in the era of immunodeficiency: challenges and opportunities for treatment and prevention.Annals of medicine and surgery (2012) · 2026Article
- Kaposi Sarcoma-Associated Immune Reconstitution Inflammatory Syndrome (KS-IRIS) in Advanced HIV: Challenges in Managing Visceral Disease With Pericardial Involvement.Open forum infectious diseases · 2026Article
- From Effusion to Conclusion: Diagnosis of Intrathoracic Kaposi Sarcoma With Video-Assisted Thoracoscopic Surgery.Annals of thoracic surgery short reports · 2026Article
- Article
- Clinical Predictors and Incidence of Kaposi Sarcoma Among Males With HIV in the Treat-All Era in the United States and Canada.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Article
- Characteristics and outcomes of Kaposi sarcoma herpesvirus-associated inflammatory cytokine syndrome.Blood advances · 2025Article
- Cutaneous manifestations associated with unknown HIV infection: a case report.Dermatology reports · 2025Article
- Laser Therapy Approaches in the Treatment of Kaposi's Sarcoma: A Comprehensive Review of Dermatologic Options.Dermatology practical & conceptual · 2025Review
- Article
- A Case of HIV with Unmasked Kaposi's Sarcoma IRIS and Drug-Resistant Tuberculosis.Infectious diseases & clinical microbiology · 2025Article
- HIV-associated cancers and lymphoproliferative disorders caused by Kaposi sarcoma herpesvirus and Epstein-Barr virus.Clinical microbiology reviews · 2024Review
- Similar Viral and Immune Characteristics of Kaposi Sarcoma in ART-treated People Living With HIV and Older Patients With Classic Kaposi Sarcoma.Open forum infectious diseases · 2024Article
- Keeping an Eye Out for KS-IRIS: Kaposi Sarcoma in a Patient with Mpox.Journal of general internal medicine · 2024Article
- Nab-Paclitaxel for Relapsed AIDS-Related Kaposi Sarcoma -A Case Report.Infection and drug resistance · 2024Article
- Article
- Non-Cutaneous Visceral Kaposi's Sarcoma Diagnosis Confounded by Mycobacterium Avium Complex Lymphadenitis.Cureus · 2023Article
- Kaposi Sarcoma in a Child after Fanconi Anemia-Induced Haploidentical Hematopoietic Stem Cell Transplant: A Case Report.Children (Basel, Switzerland) · 2023Article
- Kaposi Sarcoma, a Trifecta of Pathogenic Mechanisms.Diagnostics (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
People living with HIV (PLWH) with advanced immunosuppression who initiate antiretroviral therapy (ART) are susceptible to the occurrence of an immune reconstitution inflammatory syndrome (IRIS). Although ART is responsible for AIDS- associated Kaposi sarcoma (KS) improvement and resolution, new onset (unmasking KS-IRIS) or sudden progression of preexisting KS (paradoxical KS-IRIS) can occur after a time delay of between a few days and 6 months after the initiation or resumption of ART, even in patients with a low degree of immunocompromise. KS-IRIS incidence varies from 2.4% to 39%, depending on study design, populations, and geographic regions. Risk factors for developing KS-IRIS include advanced KS tumor stage (T1), pre-treatment HIV viral load >5 log
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.